Literature DB >> 20104184

Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.

Mario Guslandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20104184     DOI： 10.1097/MCG.0b013e3181cb4233

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  14 in total

1.  Rifaximin for inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

Review 3.  Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease.

Authors:  Alexa R Weingarden; Byron P Vaughn
Journal:  Gut Microbes       Date:  2017-02-10

Review 4.  Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.

Authors:  Daisy Jonkers; John Penders; Ad Masclee; Marieke Pierik
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

Review 5.  Antibiotics and probiotics in inflammatory bowel disease: when to use them?

Authors:  Bincy Abraham; Eamonn M M Quigley
Journal:  Frontline Gastroenterol       Date:  2019-03-22

6.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

Review 7.  Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.

Authors:  Mario Matijašić; Tomislav Meštrović; Mihaela Perić; Hana Čipčić Paljetak; Marina Panek; Darija Vranešić Bender; Dina Ljubas Kelečić; Željko Krznarić; Donatella Verbanac
Journal:  Int J Mol Sci       Date:  2016-04-19       Impact factor: 5.923

8.  Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats.

Authors:  Artur Dembiński; Zygmunt Warzecha; Piotr Ceranowicz; Marcin Dembiński; Jakub Cieszkowski; Tomasz Gosiewski; Małgorzata Bulanda; Beata Kuśnierz-Cabala; Krystyna Gałązka; Peter Christopher Konturek
Journal:  Gastroenterol Res Pract       Date:  2016-06-28       Impact factor: 2.260

9.  Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation.

Authors:  Xinhua Chen; Guoxun Yang; Joo-Hye Song; Hua Xu; Dan Li; Jeffrey Goldsmith; Huiyan Zeng; Patricia A Parsons-Wingerter; Hans-Christian Reinecker; Ciaran P Kelly
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

Review 10.  The role of probiotics and prebiotics in inducing gut immunity.

Authors:  Angélica T Vieira; Mauro M Teixeira; Flaviano S Martins
Journal:  Front Immunol       Date:  2013-12-12       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.